Evidence map›Paper›PMID 32352084›Full record

ArticleBiomarkers journal2019

c-FLIP, a Novel Biomarker for Cancer Prognosis, Immunosuppression, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), and a Rationale Therapeutic Target.

Ahmad R Safa, Krzysztof Kamocki, M Reza Saadatzadeh, Khadijeh Bijangi-Vishehsaraei

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ahmad R SafaDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, USA.
Krzysztof KamockiDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, USA.
M Reza SaadatzadehDepartment of Neurosurgery, Indiana University School of Medicine, Indianapolis, USA.
Khadijeh Bijangi-VishehsaraeiDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, USA.
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

Role of Proteinase-3 in Apoptosis and Drug ResistanceR01CA101743 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAFA, AHMAD R · 2003 to 2007
$1.5M
DRUG RESISTANCE DUE TO LOSS OF BETA2 MICROGLOBULINR01CA080734 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SAFA, AHMAD R · 1999 to 2005
$1.4M
The Role of MEF1 in Multidrug ResistanceR01CA090878 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAFA, AHMAD R · 2001 to 2004
$1.1M
NCI NIH HHS R01 CA080734NCI NIH HHS R01 CA090878NCI NIH HHS R01 CA101743
6 · The paper itself

Abstract

Dysregulation of c-FLIP (cellular FADD-like IL-1β-converting enzyme inhibitory protein) has been shown in several diseases including cancer, Alzheimer's disease, and chronic obstructive pulmonary disease (COPD). c-FLIP is a critical anti-cell death protein often overexpressed in tumors and hematological malignancies and its increased expression is often associated with a poor prognosis. c-FLIP frequently exists as long (c-FLIP

Indexed as

Antiapoptotic proteinsApoptosisCancer biomarkerc-FLIPCytokine resistanceDeath receptor pathwaysDrug resistance

Identifiers

PMID32352084
PMCPMC7189798
OpenAlexW2948548715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.